KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (2017 - 2026)

Aquestive Therapeutics has reported Shares Outstanding over the past 9 years, most recently at $122.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 33.51% year-over-year to $122.0 million; the TTM value through Dec 2025 reached $122.0 million, up 33.51%, while the annual FY2025 figure was $122.0 million, 33.51% up from the prior year.
  • Shares Outstanding for Q4 2025 was $122.0 million at Aquestive Therapeutics, roughly flat from $121.7 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $122.0 million in Q4 2025 and troughed at $36.2 million in Q1 2021.
  • A 5-year average of $71.0 million and a median of $64.2 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: increased 7.92% in 2021 and later soared 61.79% in 2024.
  • Year by year, Shares Outstanding stood at $41.2 million in 2021, then soared by 32.98% to $54.8 million in 2022, then increased by 25.0% to $68.5 million in 2023, then skyrocketed by 33.39% to $91.4 million in 2024, then skyrocketed by 33.51% to $122.0 million in 2025.
  • Business Quant data shows Shares Outstanding for AQST at $122.0 million in Q4 2025, $121.7 million in Q3 2025, and $99.4 million in Q2 2025.